Permian Resources Corporation Class A PR 深 滬
等待開盤 03-26 09:30:00 美东时间
20.92
+0.240
+1.16%
華盛通- 最 高20.92
- 今 開20.40
- 成交量 937.65万股
- 最 低 20.40
- 昨 收 20.68
- 總市值 169.87亿
- 52周最高 20.92
- 市盈率 靜 16.35
- 換手率 0.00%
- 52周最低 9.40
- 委 比 29.55%
- 總股本 8.12亿
- 歷史最高 21.23
- 量 比 0.53
- 振 幅 2.51%
- 歷史最低 -1.655
- 每 手 1
- 風險率 2.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Google Accelerates Quantum Timeline: New Dual-Track Strategy Aims For 2030 Commercial Breakthrough
Alphabet (GOOGL) is expanding its Quantum AI program to include neutral atoms. Discover how this dual-track hardware approach and a new Boulder-based leadership team are fueling a 1.1% stock jump.
03-25 19:39
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Truist Securities Initiates Coverage On Permian Resources with Buy Rating, Announces Price Target of $24
Truist Securities analyst Gabe Daoud initiates coverage on Permian Resources (NYSE:PR) with a Buy rating and announces Price Target of $24.
03-25 00:11
Goldman Sachs Raises Oil Price Forecasts – Picks 7 Winners Among Energy Stocks
Goldman raised Brent to $100 for Q2 2026 and sees 22% average total return in top E&P names, anchored to a conservative $75/bbl mid-cycle assumption.
03-24 03:55
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Goldman Sachs Maintains Buy on Permian Resources, Raises Price Target to $22
Goldman Sachs analyst Neil Mehta maintains Permian Resources (NYSE:PR) with a Buy and raises the price target from $17 to $22.
03-12 02:02
